Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd banner

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874
Watchlist
Price: 16.71 HKD -0.95%
Market Cap: HK$41.1B

EV/FCFF

-22.5
Current
234%
Cheaper
vs 3-y average of 16.8

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-22.5
=
Enterprise Value
HK$34.2B
/
Free Cash Flow to Firm
¥-1.5B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-22.5
=
Enterprise Value
HK$34.2B
/
Free Cash Flow to Firm
¥-1.5B

Valuation Scenarios

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (16.8), the stock would be worth HK$-12.43 (174% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-236%
Maximum Upside
No Upside Scenarios
Average Downside
199%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple -22.5 HK$16.71
0%
3-Year Average 16.8 HK$-12.43
-174%
5-Year Average 12.8 HK$-9.49
-157%
Industry Average 30.7 HK$-22.75
-236%
Country Average 28.8 HK$-21.35
-228%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HKEX:874
37.2B HKD -22.5 12.3
US
Eli Lilly and Co
NYSE:LLY
883B USD 153.6 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 29.4 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 35.4 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 24.5 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 19.6 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 44.6 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 22 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 12 17.3

Market Distribution

Lower than 100% of companies in China
Percentile
0th
Based on 4 731 companies
0th percentile
-28.4
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View

Market Cap
41.1B HKD
Industry
Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stands as a prominent player in China's healthcare industry, weaving a rich legacy that dates back to its formation in the 20th century. Rooted in the dynamic city of Guangzhou, Baiyunshan reflects a harmonious blend of traditional Chinese medicine (TCM) and modern pharmaceutical innovation. The company's name itself, Baiyunshan—meaning "White Cloud Mountain" in Chinese—symbolizes its foundational connection to the city's cultural heritage and its aspiration to elevate healthcare standards. Baiyunshan's operations are a testament to its multifaceted approach to pharmaceutical production. It delves into the research and development, manufacturing, and distribution of both TCM and Western medicine. This dual approach enables Baiyunshan to cater to a diverse demographic, forging a unique path by merging ancient medical wisdom with cutting-edge scientific advancements. The core of Baiyunshan's business strategy pivots around its expansive product portfolio, which is instrumental in its revenue generation. Pharmaceuticals are at its heart, encompassing a wide range of products from patent medicines to essential drugs that are household names in China. Additionally, the company has successfully branched into the production of over-the-counter (OTC) products, health supplements, and even skincare products, broadening its consumer reach. Meanwhile, Baiyunshan's distribution network—extensive and strategically aligned—stretches across domestic and international markets, ensuring its products are widely accessible. By leveraging strategic partnerships and ongoing innovation, the company continually fortifies its market presence, making Baiyunshan a notable financial performer and a beacon of trust in the healthcare industry.

Intrinsic Value
25.42 HKD
Undervaluation 34%
Intrinsic Value
Price HK$16.71
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett